tepotinib
Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients
Premium
Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance.
Amoy Diagnostics CDx Gets Japanese Approval to ID NSCLC Patients Eligible for Tepmetko
The Japanese Ministry of Health, Labor, and Welfare has approved AmoyDx's PLC Panel for use in identifying NSCLC patients with MET exon 14 skipping alterations.
Amoy Diagnostics, Merck KGaA Partner for Lung Cancer Companion Diagnostic Development in China
AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib.
AmoyDx Strikes CDx Development Deal for Merck KGaA Cancer Drug
AmoyDx aims to develop a companion diagnostic for Merck KGaA's non-small cell lung cancer treatment Tepmetko, which was recently approved in Japan.
Japanese Regulators Approve Merck KGaA MET Inhibitor With ArcherDx CDx
The drug, tepotinib, will now be available to treat advanced non-small cell lung cancer patients in Japan with MET exon 14 skipping alterations.